<DOC>
	<DOCNO>NCT00236561</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy two dos topiramate ( 100 200 mg daily ) versus placebo propranolol prevention migraine . The study also assess dose response relationship topiramate , estimate relative efficacy topiramate versus propranolol prevention migraine , evaluate effect migraine prevention topiramate versus placebo Health Related Quality Life .</brief_summary>
	<brief_title>A Study Efficacy Safety Two Doses Topiramate Compared Placebo Propranolol Prevention Migraine</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group , multicenter study evaluate efficacy safety two dos topiramate versus placebo propranolol prevention migraine headache . The study consist 4 phase : Baseline Phase ( evaluation eligibility criterion taper migraine prophylaxis medication patient take ) , Core Double-Blind Phase ( patient randomize receive either 100 milligram [ mg ] /day topiramate , 200mg/day topiramate , 160mg/day propranolol placebo total 26 week ) , Blinded Extension Phase ( patient continue dose medication sponsor terminates study patient withdraws study ) , Taper/Exit Phase ( medication patient exit study taper 7 week ) . The primary hypothesis one two topiramate dos ( 100 , 200 mg/day ) superior placebo prophylaxis migraine base change monthly ( 28 day ) migraine period rate prospective Baseline Phase Core Double-Blind Phase . Oral medication ( 100 milligram [ mg ] /day topiramate , 200mg/day topiramate , 160mg/day propranolol , placebo ) 26-weeks Core Double-Blind Phase . Doses may continue termination study withdrawal patient Blinded Extension Phase .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Medical history consistent migraine without aura accord International Headache Society ( IHS ) least 1 year prior study Between 3 12 migraine period great 15 headache day ( migraine nonmigraine ) per month Baseline Phase No clinically significant abnormality neurological exam , electrocardiogram ( ECG ) clinical laboratory test result baseline Female patient must postmenopausal least 1 year , surgically incapable childbearing , practice abstinence , practice acceptable method contraception ( require negative pregnancy test ) Patients headache migraine Patients episodic tension sinus headache Onset migraine age 50 year Patients fail two adequate regimen migraine prophylaxis Patients overuse pain medication certain medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Common Migraine</keyword>
	<keyword>Classic Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Propranolol</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Prevention</keyword>
</DOC>